Randomized Trial of Wound Infiltration With Extended-release Bupivacaine Before Laparoscopic or Robotic Hysterectomy

• Status: Completed
• Trial end date: 2016-02-01
• Target enrollment: 0
• Participant gender: Female

Summary

The investigators are studying ways to improve pain control after surgery. One way to decrease pain is to inject incisions with a numbing medicine (local anesthetic) while in the operating room. There is an FDA approved extended-release version of a commonly used local anesthetic (bupivacaine) that can last for 4 days instead of 6 hours. The investigators are studying whether using the extended-release medication (Exparel) will give better pain relief after laparoscopic and robotic-assisted hysterectomies.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: AdventHealth; Florida Hospital
• Treatments: Bupivacaine

Criteria

Inclusion Criteria:

1. Benign indication for surgery

2. Planned multiport laparoscopic or robotic assisted hysterectomy

3. Non-pregnant

4. Able to provide informed consent

5. Owns smartphone or computer with internet access

6. Willing to provide contact phone number and accept SMS text messages

7. Ability to speak and read English (because texts and online surveys will be in English only)

Exclusion Criteria:

1. Planned additional procedures (e.g. incontinence surgery, prolapse repair or bowel surgery)

2. Contraindication to study drug

1. Severe Hepatic disease

2. Severe Kidney disease

3. Current use of monoamine oxidase inhibitors

4. Current use of tricyclic antidepressants

3. History of substance or alcohol abuse within the past 2 years